XML 91 R68.htm IDEA: XBRL DOCUMENT
v3.25.2

Subsequent Events (Additional Information (Details) | Apr. 17, 2025 shares | Feb. 28, 2025 Days | Feb. 22, 2025 USD ($) | Jan. 02, 2025 USD ($) shares | Feb. 29, 2024 $ / shares shares | Mar. 31, 2025 shares | Jan. 21, 2025 shares | Dec. 31, 2024 shares | Jun. 18, 2024 shares | Jun. 11, 2024 shares | Dec. 31, 2023 shares | Oct. 11, 2023 $ / shares | Sep. 25, 2023 shares | Sep. 21, 2023 shares
--- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | ---
Subsequent Event [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Amortization payment | $ |  |  |  | $ 1,100,000 |  |  |  |  |  |  |  |  |  |
Class of Warrant or Right, Outstanding |  |  |  |  |  |  |  | 5,467,692 |  |  | 6,854,309 |  |  |
Common Warrants Purchase |  |  |  |  |  |  |  | 7,142 |  |  |  |  |  |
Combined Price Paid Of Warrant | $ / shares |  |  |  |  | $ 54.74 |  |  |  |  |  |  |  |  |
Common stock, shares issued |  |  |  |  |  | 6,951,622 |  | 6,951,622 | 3,250,000 | 3,250,000 |  |  | 13,562 | 8,500,000
Maximum [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Subsequent Event [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Debt conversion price | $ / shares |  |  |  |  |  |  |  |  |  |  |  | $ 70 |  |
Minimum [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Subsequent Event [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Debt conversion price | $ / shares |  |  |  |  |  |  |  |  |  |  |  | $ 17.5 |  |
Scilex Pharma [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Subsequent Event [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Total Number of Shares Granted |  |  |  | 142,855 |  |  |  |  |  |  |  |  |  |
Rodman & Renshaw LLC |  |  |  |  |  |  |  |  |  |  |  |  |  |
Subsequent Event [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Common stock sold |  |  |  |  | 168,068 |  |  |  |  |  |  |  |  |
Common Warrants Purchase |  |  |  |  | 168,068 |  |  |  |  |  |  |  |  |
Public Offering Price | $ / shares |  |  |  |  | $ 59.5 |  |  |  |  |  |  |  |  |
ZTlido Rest of World License Agreement [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Subsequent Event [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Percentage of Lidocaine Topical System |  |  | 1.80% |  |  |  |  |  |  |  |  |  |  |
Aggregate Payment Of Company | $ |  |  | $ 200,000 |  |  |  |  |  |  |  |  |  |  |
ZTlido Rest of World License Agreement [Member] | Scilex Pharma [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Subsequent Event [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Percentage of net revenue |  |  | 50.00% |  |  |  |  |  |  |  |  |  |  |
ZTlido Rest of World License Agreement [Member] | Forecast [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Subsequent Event [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Percentage of Lidocaine Topical System |  |  | 1.80% |  |  |  |  |  |  |  |  |  |  |
Aggregate Payment Of Company | $ |  |  | $ 200,000 |  |  |  |  |  |  |  |  |  |  |
ZTlido Rest of World License Agreement [Member] | Forecast [Member] | Scilex Pharma [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Subsequent Event [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Percentage of net revenue |  |  | 50.00% |  |  |  |  |  |  |  |  |  |  |
Gloperba-Elyxyb Royalty Purchase Agreement [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Subsequent Event [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Percentage of aggregate net sales |  | 4.00% |  |  |  |  |  |  |  |  |  |  |  |
No of calendar days | Days |  | 60 |  |  |  |  |  |  |  |  |  |  |  |
Gloperba-Elyxyb Royalty Purchase Agreement [Member] | Forecast [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Subsequent Event [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Percentage of aggregate net sales |  | 4.00% |  |  |  |  |  |  |  |  |  |  |  |
No of calendar days | Days |  | 60 |  |  |  |  |  |  |  |  |  |  |  |
Deferral and Consent Under Tranche B Senior Secured Convertible Note [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Subsequent Event [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Initial principal amount | $ |  |  |  | $ 6,250,000 |  |  |  |  |  |  |  |  |  |
Redemption Premium |  |  |  | 100.00% |  |  |  |  |  |  |  |  |  |
Common Stock [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Subsequent Event [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Shares delivered |  |  |  |  |  | 92,857 |  |  |  |  |  |  |  |
Subsequent Event [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Subsequent Event [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Amortization payment | $ |  |  |  | $ 1,100,000 |  |  |  |  |  |  |  |  |  |
Ownership Interest Rate | 60.00% |  |  |  |  |  |  |  |  |  |  |  |  |
Subsequent Event [Member] | Three i LP [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Subsequent Event [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Total Number of Shares Granted |  |  |  | 14,285 |  |  |  |  |  |  |  |  |  |
Subsequent Event [Member] | Scilex Pharma [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Subsequent Event [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Total Number of Shares Granted |  |  |  | 142,855 |  |  |  |  |  |  |  |  |  |
Subsequent Event [Member] | Oramed [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Subsequent Event [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Total Number of Shares Granted |  |  |  | 71,428 |  |  |  |  |  |  |  |  |  |
Subsequent Event [Member] | BPY Limited [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Subsequent Event [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Total Number of Shares Granted |  |  |  | 20,571 |  |  |  |  |  |  |  |  |  |
Subsequent Event [Member] | Nomis Bay Ltd [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Subsequent Event [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Total Number of Shares Granted |  |  |  | 36,571 |  |  |  |  |  |  |  |  |  |
Subsequent Event [Member] | Scilex Bio JV |  |  |  |  |  |  |  |  |  |  |  |  |  |
Subsequent Event [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Ownership Interest Rate | 40.00% |  |  |  |  |  |  |  |  |  |  |  |  |
Common stock, shares issued | 5,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |
Subsequent Event [Member] | Deferral and Consent Under Tranche B Senior Secured Convertible Note [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Subsequent Event [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Initial principal amount | $ |  |  |  | $ 6,250,000 |  |  |  |  |  |  |  |  |  |
Redemption Premium |  |  |  | 100.00% |  |  |  |  |  |  |  |  |  |
Subsequent Event [Member] | Common Stock [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Subsequent Event [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Shares delivered |  |  |  |  |  |  | 92,857 |  |  |  |  |  |  |

X
- Definition Aggregate Payment Of Company + References No definition available. + Details
Name: | sclx_AggregatePaymentOfCompany
Namespace Prefix: | sclx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Combined Price Paid Of Warrant + References No definition available. + Details
Name: | sclx_CombinedPricePaidOfWarrant
Namespace Prefix: | sclx_
Data Type: | dtr-types:perShareItemType
Balance Type: | na
Period Type: | instant

X
- Definition Common stock sold. + References No definition available. + Details
Name: | sclx_CommonStockSold
Namespace Prefix: | sclx_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition No of Calendar Days + References No definition available. + Details
Name: | sclx_NoOfCalendarDays
Namespace Prefix: | sclx_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Ownership Interest Rate + References No definition available. + Details
Name: | sclx_OwnershipInterestRate
Namespace Prefix: | sclx_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage of Lidocaine Topical System + References No definition available. + Details
Name: | sclx_PercentageOfLidocaineTopicalSystem
Namespace Prefix: | sclx_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Public Offering Price + References No definition available. + Details
Name: | sclx_PublicOfferingPrice
Namespace Prefix: | sclx_
Data Type: | dtr-types:perShareItemType
Balance Type: | na
Period Type: | instant

X
- Definition Purchase Of Common Warrants + References No definition available. + Details
Name: | sclx_PurchaseOfCommonWarrants
Namespace Prefix: | sclx_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- Definition Shares Delivered + References No definition available. + Details
Name: | sclx_SharesDelivered
Namespace Prefix: | sclx_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- Definition Total Number of Shares Granted + References No definition available. + Details
Name: | sclx_TotalNumberOfSharesGranted
Namespace Prefix: | sclx_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of warrants or rights outstanding. + References No definition available. + Details
Name: | us-gaap_ClassOfWarrantOrRightOutstanding
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- Definition Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details
Name: | us-gaap_CommonStockSharesIssued
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- Definition Amount of expense for allocation of cost of intangible asset over its useful life directly used in production of good and rendering of service. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details
Name: | us-gaap_CostOfGoodsAndServicesSoldAmortization
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The price per share of the conversion feature embedded in the debt instrument. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-5 + Details
Name: | us-gaap_DebtInstrumentConvertibleConversionPrice1
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:perShareItemType
Balance Type: | na
Period Type: | instant

X
- Definition Face (par) amount of debt instrument at time of issuance. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2 + Details
Name: | us-gaap_DebtInstrumentFaceAmount
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Percentage price of original principal amount of debt at which debt can be redeemed by the issuer. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 470 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477734/942-470-50-3 + Details
Name: | us-gaap_DebtInstrumentRedemptionPricePercentage
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage of stated interest rate for receivables from retail land sales. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 976 -SubTopic 310 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477332/976-310-50-1 + Details
Name: | us-gaap_RetailLandSalesReceivablesStatedInterestRate
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Percentage of remaining performance obligation to total remaining performance obligation not recognized as revenue. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b)(1) -SubTopic 10 -Topic 606 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-13 + Details
Name: | us-gaap_RevenueRemainingPerformanceObligationPercentage
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481674/830-30-50-2 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 855 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2 + Details
Name: | us-gaap_SubsequentEventLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=sclx_ScilexPharmaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=sclx_RodmanRenshawLlcMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=sclx_ZTlidoRestOfWorldLicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementScenarioAxis=srt_ScenarioForecastMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=sclx_Gloperba-ElyxybRoyaltyPurchaseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_LongtermDebtTypeAxis=sclx_DeferralAndConsentUnderTrancheBSeniorSecuredConvertibleNoteMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=sclx_ThreeILpMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=sclx_OramedMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=sclx_BpyLimitedMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=sclx_NomisBayLtdMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=sclx_ScilexBioJVMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |